Omid Farokhzad Sells 33,838 Shares of Seer (NASDAQ:SEER) Stock

by · The Cerbat Gem

Seer, Inc. (NASDAQ:SEER – Get Free Report) CEO Omid Farokhzad sold 33,838 shares of the stock in a transaction that occurred on Wednesday, November 19th. The shares were sold at an average price of $1.97, for a total transaction of $66,660.86. Following the completion of the transaction, the chief executive officer owned 1,238,230 shares in the company, valued at $2,439,313.10. This represents a 2.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Seer Price Performance

Shares of Seer stock traded up $0.03 on Friday, hitting $1.97. 166,159 shares of the company’s stock traded hands, compared to its average volume of 198,122. The firm’s 50-day moving average price is $2.17 and its two-hundred day moving average price is $2.12. The stock has a market capitalization of $109.91 million, a PE ratio of -1.45 and a beta of 1.59. Seer, Inc. has a one year low of $1.62 and a one year high of $2.63.

Seer (NASDAQ:SEER – Get Free Report) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.01. The business had revenue of $4.12 million for the quarter, compared to analyst estimates of $4.00 million. Seer had a negative return on equity of 25.88% and a negative net margin of 484.51%. Seer has set its FY 2025 guidance at EPS. On average, analysts forecast that Seer, Inc. will post -1.42 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Seer in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

Get Our Latest Research Report on Seer

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its holdings in shares of Seer by 0.9% in the third quarter. Vanguard Group Inc. now owns 2,221,404 shares of the company’s stock worth $4,820,000 after acquiring an additional 18,760 shares in the last quarter. Bridgeway Capital Management LLC grew its position in shares of Seer by 15.5% in the 2nd quarter. Bridgeway Capital Management LLC now owns 837,443 shares of the company’s stock valued at $1,792,000 after purchasing an additional 112,100 shares during the period. Geode Capital Management LLC grew its position in shares of Seer by 16.5% in the 2nd quarter. Geode Capital Management LLC now owns 509,727 shares of the company’s stock valued at $1,091,000 after purchasing an additional 72,265 shares during the period. Jacobs Levy Equity Management Inc. increased its stake in Seer by 124.5% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 363,355 shares of the company’s stock worth $614,000 after purchasing an additional 201,491 shares in the last quarter. Finally, Jane Street Group LLC raised its holdings in Seer by 33.3% during the 1st quarter. Jane Street Group LLC now owns 254,174 shares of the company’s stock worth $430,000 after buying an additional 63,432 shares during the period. 75.20% of the stock is currently owned by institutional investors.

About Seer

(Get Free Report)

Seer, Inc, a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.

Further Reading